Stock A175250 ICURE PHARMACEUTICAL INCORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Icure Pharmaceutical Incorporation

Equities

A175250

KR7175250000

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 09/05/2024 am IST 		5-day change 1st Jan Change
1,843 KRW -0.27% Intraday chart for Icure Pharmaceutical Incorporation -2.69% -11.82%
20/03 Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Icure Pharmaceutical Incorporation(KOSDAQ:A175250) dropped from S&P Global BMI Index
CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Icure Pharmaceutical Incorporation announced that it has received KRW 5 billion in funding
CI
Icure Pharmaceutical Incorporation announced that it expects to receive KRW 5 billion in funding
CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Icure Pharmaceutical to Raise $57 Million from Share Sale
MT
Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Tranche Update on Icure Pharmaceutical Incorporation's Equity Buyback Plan announced on February 25, 2022.
CI
Icure Pharmaceutical Incorporation's Equity Buyback announced on February 25, 2022, has closed with 40,323 shares, representing 0.23% for KRW 547.51 million.
CI
Icure Pharmaceutical Incorporation announces an Equity Buyback for 40,323 shares.
CI
Icure Pharmaceutical Incorporation authorizes a Buyback Plan.
CI
Icure Acquires Drug Product Approval for Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea
CI
Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Cosnine Co., Ltd. announced that it has received KRW 6.0116 billion in funding from Icure Pharmaceutical Incorporation
CI
Cosnine Co., Ltd. announced that it expects to receive KRW 6.0116 billion in funding from Icure Pharmaceutical Incorporation
CI
Icure Pharmaceutical Incorporation announced that it has received KRW 50 billion in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A175250 Stock
  4. News Icure Pharmaceutical Incorporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW